title: Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study).
abstract: OBJECTIVE
  (1) To improve survival rates in patients with Ewing's sarcoma (ES) or peripheral neuroectodermal tumours (PNET) using semi-continuous chemotherapy and aiming to perform surgery in all; (2) To identify early prognostic factors to tailor therapy for future studies.
  
  
  METHODS
  One hundred and forty-one patients were entered onto the trial between January 1988 and December 1991. Induction therapy consisted of five courses of Cytoxan, 150 mg/m(2) x 7 days, followed by Doxorubicin, 35 mg/m(2) i.v on day 8 given at short intervals. Surgery was recommended whenever possible. The delivery of radiation therapy was based on the quality of resection and the histological response to CT. Maintenance chemotherapy consisted of vincristine + actinomycin and cytoxan + doxorubicin. The total duration of therapy was 10 months.
  
  
  RESULTS
  After a median follow-up of 8.5 years, the projected overall survival at 5 years was 66% and disease-free survival (DFS) was 58%. In patients treated by surgery, only the histological response to CT had an influence on survival: 75% DFS for patients with a good histological response (less than 5% of cells), 48% for intermediate responders and only 20% for poor responders (> or = 30% of cells), P < 0.0001. The initial tumor volume by itself had no influence on DFS in these patients. In contrast, the tumour volume had a strong impact on DFS in patients treated by radiation therapy alone. Age had no impact on outcome.
  
  
  CONCLUSIONS
  Therapeutic trials for localized Ewing's sarcoma should be based on the histological response to chemotherapy or on the tumour volume according to the modality used for local therapy.
authors.affiliation: Pédiatrie Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cedex, France.
authors.forename: O
authors.initials: O
authors.lastname: Oberlin
authors.forename: M C
authors.initials: MC
authors.lastname: Deley
authors.forename: B N
authors.initials: BN
authors.lastname: Bui
authors.forename: J C
authors.initials: JC
authors.lastname: Gentet
authors.forename: T
authors.initials: T
authors.lastname: Philip
authors.forename: P
authors.initials: P
authors.lastname: Terrier
authors.forename: C
authors.initials: C
authors.lastname: Carrie
authors.forename: F
authors.initials: F
authors.lastname: Mechinaud
authors.forename: C
authors.initials: C
authors.lastname: Schmitt
authors.forename: A
authors.initials: A
authors.lastname: Babin-Boillettot
authors.forename: J
authors.initials: J
authors.lastname: Michon
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D018241:Neuroectodermal Tumors, Primitive, Peripheral / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D011379:Prognosis; D011878:Radiotherapy; D012512:Sarcoma, Ewing / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide